Skip to main content
. 2021 Jun 14;91(2):283–288. doi: 10.1038/s41390-021-01620-5

Fig. 2. The PERSEVERE II decision tree.

Fig. 2

All patients begin at the root node and are subsequently partitioned to daughter nodes using biomarker-based criteria as indicated at the top of each node. All biomarker data are shown as pg/ml, and platelet data are shown as the number of platelets (K/μl). Daughter nodes that can no longer be partitioned are called terminal nodes (TNs) and shown in red outline. The terminal nodes are used to assign a baseline mortality probability to a patient classified to a given terminal node. The baseline mortality probability (MP) corresponding to each terminal node is indicated in red font within each terminal node and is derived from the published PERSEVERE II model. These baseline mortality risks are used for the construction of the AUROC. For calculation of the diagnostic test characteristics, the mortality probability is dichotomized into those who are predicted to survive and those who are predicted to not survive by 28 days. Patients allocated to TN1, TN2, TN5, and TN8 (mortality risk 0.000–0.019) are classified as predicted survivors. Patients allocated to TN3, TN4, TN6, TN7, and TN9 are classified as predicted non-survivors (mortality risk 0.167–0.444).